SBI
仲恩生醫科技股份有限公司
SBI is a Taiwan Emerging Stock Board biotechnology company; its most advanced asset is Stemchymal (Manufacturing and marketing authorization application submitted, Spinocerebellar ataxia), as of 2026-11-01.
Pipeline
| Asset | Target / mechanism | Stage | Indication | Region | Source date | Source |
|---|---|---|---|---|---|---|
| Stemchymal | — | Manufacturing and marketing authorization application submitted | Spinocerebellar ataxia | Japan | 2026-06-24 | Company disclosure |
Key events
- Business update (company filing)
Related Drugnews articles
No related articles in this language.